Collegium Pharmaceutical, Inc: Form 10-K for the period ended Dec 31, 2015
Filed with the SEC on Mar 18, 2016 and accepted by EDGAR at Mar 18, 2016, 17:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2015-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2015-10-01 to 2015-12-31 | $1.5m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 12 months2015-01-01 to 2015-12-31 | $8.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2015-10-01 to 2015-12-31 | −$9.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2015-01-01 to 2015-12-31 | −$26.9m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months2015-10-01 to 2015-12-31 | −$9.5m | us-gaap:NetIncomeLoss |
| Net income | 12 months2015-01-01 to 2015-12-31 | −$27.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2015-10-01 to 2015-12-31 | −$0.46 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2015-01-01 to 2015-12-31 | −$1.48 | us-gaap:EarningsPerShareBasicAndDiluted |
| Basic EPS | 3 months2015-10-01 to 2015-12-31 | −$0.46 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2015-10-01 to 2015-12-31 | 20,558,205 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 12 months2015-01-01 to 2015-12-31 | $362.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2015-12-31 | $95.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2015-12-31 | $96.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2015-12-31 | $97.7m | us-gaap:Assets |
| Current liabilities | At period end2015-12-31 | $8.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2015-12-31 | $12.6m | us-gaap:Liabilities |
| Current portion of debt | At period end2015-12-31 | $2.7m | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2015-12-31 | $85.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001558370-16-004252. Last ingested by Listed: Nov 10, 2026, 23:07 ET. Listed shows no prices and gives no investment advice.